Paper Details

  1. Home
  2. Paper Details

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.

Author: , ArnesonCarl, FeldmanJeremy, JingZhi-Cheng, KielyDavid G, KotlyarEugene, LaliberteKevin, McSwainC Shane, PanLei, RubinLewis J, TapsonVictor F, XuKai-Feng

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy and safety of oral treprostinil, a sustained-release formulation of treprostinil, in patients with pulmonary arterial hypertension (PAH). Oral treprostinil was found to be effective and safe in patients with PAH who were already receiving stable background therapy with endothelin receptor antagonists and/or phosphodiesterase type 5 inhibitors.
Paper Details　
Original Abstract of the Article :
Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy. Treprostinil diolamine, a sustained-release oral formulation of treprostinil, was studied to determine whether it could provide a more convenient prostac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1378/chest.12-2875

データ提供：米国国立医学図書館（NLM）

Oral Treprostinil: A Convenient Treatment Option for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH), a rare but life-threatening condition, affects the pulmonary arteries, causing high blood pressure in the lungs. This research explores the efficacy and safety of oral treprostinil, a sustained-release formulation of the prostacyclin analog treprostinil, as a convenient treatment option for patients with less severe PAH.

Evaluating Oral Treprostinil's Effectiveness in PAH

The study involved patients with PAH who were already receiving stable background therapy with endothelin receptor antagonists (ERAs) and phosphodiesterase type 5 inhibitors (PDE-5Is). The researchers evaluated the efficacy and safety of oral treprostinil in these patients, aiming to assess its potential as a more convenient treatment option compared to parenteral or inhaled formulations of treprostinil.

Oral Treprostinil: A Potential for Enhanced Convenience and Improved Outcomes

The study's findings provide valuable insights into the efficacy and safety of oral treprostinil in patients with PAH receiving background ERA and PDE-5I therapy. Oral treprostinil has the potential to offer a more convenient and effective treatment option for PAH patients, particularly those with less severe disease.

Dr.Camel's Conclusion

Navigating the complexities of PAH is like traversing a vast desert with unpredictable winds. Oral treprostinil offers a more convenient and potentially effective way to manage PAH, providing hope for improved outcomes for patients seeking relief from this challenging condition.

Date :
  1. Date Completed 2014-01-07
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

23669822

DOI: Digital Object Identifier

10.1378/chest.12-2875

Related Literature

Article Analysis
・Side Effects of treprostinil oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.